Sugi Predict

Sugi Predict / Compounds / SCHEMBL26972779

SCHEMBL26972779

SCHEMBL26972779

C[C@@H]1CN(C(=O)OC(C)(C)C)C[C@H](C)N1CC1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.52
▸ NPC1 O15118 2/20 0.52
▸ RAB9A P51151 2/20 0.52
▸ HTT P42858 1/20 0.51
▸ KDM4E B2RXH2 1/20 0.50
▸ PKM P14618 1/20 0.50
▸ CYP2C19 P33261 1/20 0.50
▸ GRIN2B Q13224 5/20 0.48
▸ YAP1 P46937 2/20 0.48
▸ PDK1 Q15118 1/20 0.48
▸ PDK2 Q15119 1/20 0.48
▸ PDK3 Q15120 1/20 0.48
▸ PDK4 Q16654 1/20 0.48
▸ JAK2 O60674 1/20 0.48
▸ JAK1 P23458 1/20 0.48
▸ CYP2D6 P10635 2/20 0.48
▸ CYP2C9 P11712 2/20 0.48
▸ STS P08842 1/20 0.48
▸ GPR119 Q8TDV5 2/20 0.47
▸ CYP3A4 P08684 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30732187 1.00 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9AHTTKDM4E
SCHEMBL31640211 1.00 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9AHTTKDM4E
SCHEMBL23860615 0.88 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL26926574 0.88 SMN1; SMN2 (0.57) SMN1; SMN2NPC1RAB9AHTTCYP2C19
SCHEMBL30706191 0.88 PDK1 (0.51) SMN1; SMN2NPC1RAB9AHTTKDM4E
SCHEMBL26927558 0.88 PDK1 (0.51) SMN1; SMN2NPC1RAB9AHTTKDM4E
SCHEMBL30706025 0.88 PDK1 (0.51) SMN1; SMN2NPC1RAB9AHTTKDM4E
SCHEMBL30731906 0.88 PDK1 (0.51) SMN1; SMN2NPC1RAB9AHTTKDM4E
SCHEMBL26924905 0.86 SMN1; SMN2 (0.48) SMN1; SMN2NPC1RAB9AHTTKDM4E
SCHEMBL22557323 0.86 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9AHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473294-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2025-11-18 — — US disclosed
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-09-04 — — US disclosed
US-20250270191-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2025-08-28 — — US disclosed
WO-2025137605-A1 COMPOUNDS FOR TARGETED DEGRADATION OF PROTO-ONCOGENE TYROSINE PROTEIN KINASE RECEPTOR C4 THERAPEUTICS, INC. (US) 2025-06-26 — — WO disclosed
EP-4536649-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 — — EP disclosed
EP-4536650-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2025-04-16 — — EP disclosed
CN-119317623-A Tricyclic quinolone BCL6 bifunctional degradation agents 树线生物科学公司 2025-01-14 — — CN disclosed
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. 2024-08-29 — — US disclosed
US-20240158405-A1 SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2024-05-16 — — US disclosed
US-11858940-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-01-02 — — US disclosed
US-11858940-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2024-01-02 — — US disclosed
WO-2023244918-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-21 — — WO disclosed
WO-2023240038-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS Treeline Biosciences, Inc. (US) 2023-12-14 — — WO disclosed
EP-4121167-A1 SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE Arvinas Operations, Inc. (US) 2023-01-25 — — EP disclosed
CN-115605267-A Selective modulators of mutant LRRK2 proteolysis and related methods of use 阿维纳斯企业公司（US） 2023-01-13 — — CN disclosed
US-20220064168-A1 SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2022-03-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240287091-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR SMN1; SMN2 4565/4885NPC1 1801/4885RAB9A 3447/4885
US-20240158405-A1 SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE LRRK2, ADRM1, CRBN SMN1; SMN2 464/4885NPC1 3009/4885RAB9A 1125/4885
US-20250276981-A1 TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR SMN1; SMN2 4565/4885NPC1 1801/4885RAB9A 3447/4885
US-20250270191-A1 QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS BCL6, BCL6B, BCOR SMN1; SMN2 4391/4885NPC1 1612/4885RAB9A 3106/4885
US-20220064168-A1 SELECTIVE MODULATORS OF MUTANT LRRK2 PROTEOLYSIS AND ASSOCIATED METHODS OF USE LRRK2, ADRM1, CRBN SMN1; SMN2 464/4885NPC1 3009/4885RAB9A 1125/4885
US-12473294-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use LRRK2, ADRM1, CRBN SMN1; SMN2 464/4885NPC1 3009/4885RAB9A 1125/4885
US-11858940-B2 Selective modulators of mutant LRRK2 proteolysis and associated methods of use LRRK2, ADRM1, CRBN SMN1; SMN2 464/4885NPC1 3009/4885RAB9A 1125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.